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Extracellular Matrix-Derived Hydrogels for the Induction
of Arteriogenesis in Peripheral Artery Disease?*Ralf A. Benndorf, MDL ower extremity peripheral artery disease(PAD) is a highly prevalent syndrome thataffects approximately 10% to 20% of all indi-
viduals older than 65 years in the United States and
Europe (1,2). Atherosclerosis is the dominant cause
of PAD and frequently leads to a progressive and
hemodynamically signiﬁcant narrowing of lower
extremity arteries that results in, for example, func-
tional impairment, claudication, and critical limb
ischemia (CLI), the latter being an important reason
for limb amputations and disability in afﬂicted pa-
tients (3). Therefore, the medical management of
PAD patients today mainly aims at: 1) slowing the pro-
gression of vascular disease by cardiovascular risk
factor control; 2) reducing the increased risk of
ischemic events caused by common comorbidities
such as cerebrovascular and coronary artery disease;
and 3) improving lower limb perfusion especially by
interventional endovascular or open surgical revascu-
larization treatment (3). However, not all PAD
patients with CLI are eligible for revascularization or
beneﬁt from this intervention. Thus, for this
subgroup of patients alternative strategies for the
improvement of limb perfusion are needed to avoid
progressive tissue damage.
Among the alternative strategies, therapeutic
neovascularization has emerged as an attractive*Editorials published in JACC: Basic to Translational Science reﬂect
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(W21029490).concept (4,5). The term therapeutic neovascularization
refers to a controlled vascular expansion in tissues
that have inadequate blood supply, via iatrogenic
induction of angiogenesis (sprouting of new blood
vessels from pre-existing ones, primarily resulting
in an increased capillary density) or arteriogenesis,
that is, the enlargement of pre-existing inter-
connecting arterioles leading to the formation of
new collateral arteries (4,6,7). In this context, early
studies have primarily focused on the therapeutic
manipulation of the angiogenic process; however,
results of clinical trials designed to substantiate
the potential beneﬁt of therapeutic angiogenesis in
PAD or coronary artery disease patient cohorts
have been disappointing (8). From these studies, it
has become increasingly clear that arteriolar
growth and maturation rather than sprouting
angiogenesis may be key to effective neo-
vascularization (4–7). Mechanistically, it has been
speculated that the predominant induction of de
novo capillary formation, as observed during
treatment with pro-angiogenic molecules, primarily
yields immature and hardly interconnected “high-
resistance” capillary networks that are not able to
restore tissue perfusion in the vascular beds of
occluded arteries (5–7). Of note, stem cell–based
salvage therapies in atherosclerotic vascular disease
(that are under active clinical investigation in PAD
patients) are hypothesized to act largely via the
enhancement of angiogenesis, as these (heteroge-
neous) cellular therapeutics have been described to
release considerable amounts of pro-angiogenic
growth factors (9).
Considering the rather limited success of angio-
genic interventions in PAD patients, therapeutic
arteriogenesis may represent a more promising
approach to normalize compromised arterial blood
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46ﬂow to ischemic tissues (4–7). Indeed, it has been
demonstrated in the clinical setting that a well-
developed collateral artery network due to efﬁcient
arteriogenesis in principle has the ability to
compensate even for the complete occlusion of large
arteries in humans (6,10). On the mechanistic level,
arteriogenesis of the adult organism is believed to
occur as a complex series of biomechanical as well as
subsequent cellular signaling events that orchestrate
a coordinated interaction of vascular as well as
nonvascular cells to induce arteriolar growth. The key
stimulus for arteriogenesis is an increase in blood
ﬂow and vascular endothelial shear stress due to the
obstruction or occlusion of an artery (4–7). Fluid shear
stress then triggers nitric oxide (NO) release from
endothelial cells and NO-related vasodilation to
further aggravate circumferential wall stress (4–7).
Endothelial shear stress additionally induces a
nuclear factor k B–dependent induction of, for
example, proinﬂammatory adhesion molecules
(ICAM-1, VCAM-1), chemokines (MCP-1), and growth
factors (PDGF-BB, angiopoietin-2) that attract mono-
cytes to the vessel and stimulate smooth muscle cell
proliferation and hypertrophy (4–7). Perivascular
recruitment of monocytes is an important event in
the arteriogenic process because these cells are a
key source of vascular endothelial growth factor A
(VEGF-A) and proteases, for example matrix metal-
loproteinase (MMP)-2, that are necessary to boost
endothelial cell proliferation in the enlarging vessel
via VEGF receptor (VEGF)-2 stimulation and to facil-
itate outward remodeling of the vessel through
breakdown of the surrounding extracellular matrix
(4–7). Finally, the self-limiting process ceases when
ﬂuid shear stress normalizes during progression of
collateral vessel diameters.
Despite recent advances in the ﬁeld of arterio-
genesis, many details of this complex process have
not been elucidated so far, and the list of suitable
targets or interventional concepts for therapeutic
manipulation of the arteriogenic process has
remained short. In this inaugural issue of JACC: Basic
to Translational Science, however, Ungerleider et al.
(11) add a new attractive interventional concept to
this list. In a set of elegant and thoroughly conducted
in vitro and in vivo experiments, they establish a
novel strategy to improve arterial blood ﬂow and
skeletal muscle remodeling in the rat model of hind-
limb ischemia via direct delivery of extracellular
matrix (ECM)-derived hydrogels to ischemic muscle
tissue.
To achieve this goal, in a ﬁrst step, decellularized
ECM were prepared from porcine skeletal muscle
tissue and human umbilical cords and furtherprocessed to yield a puriﬁed, pepsin-digested lyo-
philisate that, before its use, was converted to an
isotonic injectable hydrogel by the addition of sterile
water. A thorough characterization of these hydrogels
involving, for example, global proteomics as well as
scanning electron microscopy analyses performed
upon gelation of these hydrogels in vivo revealed
considerable differences in the molecular composi-
tion and mesh-like macrostructures of both matrices,
that is, a more close-meshed and regular structure of
the ECM-based hydrogel derived from porcine skel-
etal muscle tissue. Thus, the present study supports
the current perception that ECM compositions
considerably depend on the tissue studied and that
biomaterials derived hereof, at least in part, retain the
biomechanical and biochemical characteristics of
their original tissue source (12,13).In a subsequent set of in vivo experiments, the
impact of both hydrogel preparations on arterial
blood ﬂow recovery and blood vessel growth was
analyzed in a rat hindlimb ischemia model after a
single bolus injection of the biomaterial into the
ischemic gracilis muscle 7 days after femoral artery
ligation. In this experimental setup, perfusion of both
ischemic and healthy limbs was regularly analyzed
over a period of 6 weeks before and after the inter-
vention. Most importantly, within 3 weeks after in-
jection, both hydrogel preparations, to a similar
extent, improved arterial blood ﬂow to the ischemic
muscle tissue as compared with control in-
terventions, and this effect remained stable (or even
further increased) during the remaining 2 weeks of
the study. Additional morphometric analyses showed
a higher density of large arterioles, but no change in
the density of capillaries in the affected muscle tissue
of hydrogel-treated animals. These ﬁndings led the
authors to conclude that the (comparable) increase in
blood ﬂow induced by both hydrogels depended on
the induction of arteriogenesis rather than angio-
genesis, a conclusion that is supported by the existing
literature in that: 1) development of a functional
collateral circulation induces a signiﬁcant shift
towards an increase in arteriolar vessel size rather
than an increase in arteriolar or capillary vessel den-
sity (6,10); and 2) arteriogenesis is the most promi-
nent mechanism for blood ﬂow recovery after femoral
artery occlusion at least in small rodent models
(6,10,14). However, the fact that similar arteriogenic
effects were observed during treatment with the 2
hydrogels from different tissue sources indicates that
a common (and still unknown) ECM-derived stimulus
rather than tissue-speciﬁc ECM cues were necessary
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47to promote arteriogenesis in this model. In further
histological analyses, the authors additionally
focused on the ability of hydrogels to confer tissue
(skeletal muscle) protection. Interestingly, in this
setting skeletal muscle-derived hydrogels more
strongly improved skeletal muscle progenitor
recruitment and muscle architecture, thereby sug-
gesting that skeletal muscle–derived ECM provides
speciﬁc signals to foster skeletal muscle integrity
during tissue ischemia.
Although the study contributes several valuable
ﬁndings to the ﬁeld of arteriogenesis research, it also
has certain limitations. In this regard, one obvious
limitation of the present study is that it cannot pro-
vide a conclusive explanation for its key observa-
tions, namely the proarteriogenic properties of
acellular ECM-based hydrogels. In an attempt to ﬁll
the mechanistic gap, whole transcriptome data were
captured in ischemic muscle tissue from hydrogel-
treated and control mice 3 and 10 days after inter-
vention. These analyses yielded 2 “hard-to-interpret”
sets of transcriptome data that showed 561 differen-
tially regulated genes early after intervention,
whereas the number of differentially regulated genes
1 week hereafter dramatically decreased to 16,
thereby indicating that the early response after
hydrogel intervention may set the scene for an
efﬁcient arteriogenic response in this model. Inter-
estingly, early after the intervention, a considerable
up-regulation of several genes that have been
described (15) to enhance perivascular monocyte
recruitment during arteriogenesis, for example, Ccr2,
Ccl5, and Cxcl10, along with an up-regulation of
genes indicative of lymphocyte and smooth muscle
cell proliferation, was observed. It is therefore
tempting to speculate that the hydrogel components
or its degradation products have the ability to
enhance monocyte recruitment to sites of arteriolar
growth. Upon recruitment, these cells then secrete,
for example, VEGF-A, NO, and MMPs to stimulate
vascular cell proliferation and the outward remodel-
ing of arterioles. Nonetheless, future hypothesis-
driven studies are needed to unravel hydrogel-
related signaling pathways in skeletal muscle tissue
that foster the arteriogenic process.
Despite these limitations, the study of Ungerleider
et al. (11) goes beyond the state of the art in several
ways and may additionally have important clinical
implications. First, it discloses a previously unrecog-
nized role of acellular ECM-based hydrogels in pro-
moting arteriogenesis, blood ﬂow recovery, and
tissue protection in the setting of critical hindlimb
ischemia in vivo. As acknowledged by the authors(11,16,17), several studies have explored the role of
(less complex) biomaterials mostly as drug or cell
delivery systems in PAD-related animal models.
However, none of these studies has focused on the
inherent potential of these biomaterials to induce
blood ﬂow and affect vascular remodeling on its own.
Moreover, biomaterials and ECM-based scaffolds
have been widely used in tissue protection and repair
(also in the clinical setting) (13,16), but the relevance
of tissue source for skeletal muscle protection
conferred by ECM-based biomaterials in the context
of ischemic vascular disease has not been examined
so far. Second, this study paves the way for the
development of tissue-speciﬁc hydrogel-related drug
or cell delivery systems with superior tolerability
proﬁles, delivery systems that could be additionally
engineered to yield hydrogels with optimized bio-
molecular compositions and biomechanical proper-
ties. Finally, the study highlights a simple, yet
effective technique to induce arteriogenesis in CLI
that, in principle, allows for timely translation to the
clinical setting; a similar myocardial ECM-based
hydrogel designed by the same group has already
reached the ﬁrst phase of clinical development (16).
Nevertheless, before translation of this technique to
the clinic can take place, further information on, for
example, efﬁcacy, biocompatibility, and hemo-
compatibility, has to be captured from experiments in
pre-clinical disease and large animal models.
Taken together, this valuable contribution of
Ungerleider et al. (11) uncovers the ability of ECM-
based hydrogels to improve arterial blood ﬂow and
skeletal muscle remodeling in a pre-clinical model of
CLI via direct delivery of ECM-derived hydrogels to
ischemic muscle tissue. Several questions, including
the question of how the biomaterials exert their
effects on arterial growth and remodeling, need to be
answered in further hypothesis-driven animal studies
that could also be used to obtain important safety
information needed for further translational devel-
opment of these potential biotherapeutics. However,
as treatment options for patients with CLI remain
scarce, induction of arterial blood ﬂow to compro-
mised tissues via delivery of ECM-based hydrogels
may prove to be a valuable salvage strategy for these
patients in the future.
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